SELB - Selecta Biosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.1000
-0.0500 (-2.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1500
Open2.1400
Bid2.0000 x 1000
Ask2.9500 x 800
Day's Range2.0200 - 2.1700
52 Week Range1.4100 - 16.5450
Volume149,169
Avg. Volume414,693
Market Cap94.055M
Beta (3Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-2.3290
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.80
Trade prices are not sourced from all markets
  • The Selecta Biosciences (NASDAQ:SELB) Share Price Is Down 84% So Some Shareholders Are Rather Upset
    Simply Wall St.yesterday

    The Selecta Biosciences (NASDAQ:SELB) Share Price Is Down 84% So Some Shareholders Are Rather Upset

    Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...

  • GlobeNewswire4 days ago

    Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019

    “We continue to believe SEL-212 has the potential to change the treatment paradigm in chronic refractory gout by fulfilling several unmet needs, including sustained serum uric acid reduction, reduced painful flares and once monthly dosing. SEL-212 is a combination product candidate designed to sustain control of serum uric acid (SUA) levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity.

  • GlobeNewswire17 days ago

    Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced that CEO and President Carsten Brunn, Ph.D., will present at the Jefferies Healthcare Conference in NYC at 1:30 p.m. ET on Thursday, June 06, 2019. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity.

  • Thomson Reuters StreetEvents24 days ago

    Edited Transcript of SELB earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Selecta Biosciences Inc Earnings Call

  • GlobeNewswirelast month

    Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

    - Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 -.

  • GlobeNewswirelast month

    Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it plans to issue its first quarter 2019 financial results before the open of the U.S. financial markets on Thursday, May 09, 2019. At 8:30 a.m. ET that day, Selecta will host a conference call and live audio webcast to discuss first quarter 2019 financial results and provide a corporate update. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.

  • GlobeNewswire2 months ago

    Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting

    WATERTOWN, Mass., April 16, 2019 -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic.

  • Will Selecta Biosciences Continue to Surge Higher?
    Zacks2 months ago

    Will Selecta Biosciences Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Selecta Biosciences.

  • GlobeNewswire2 months ago

    Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that CEO and President Carsten Brunn, Ph.D., will present at the Needham & Company 18th Annual Healthcare Conference in NYC at 2:50 p.m. ET on Tuesday, April 09, 2019. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.

  • GlobeNewswire3 months ago

    Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced the initiation of a six month head-to-head clinical trial (COMPARE), designed to evaluate superiority of its lead product candidate, SEL-212 (ImmTOR + Pegadricase), compared to KRYSTEXXA, the current U.S. Food and Drug Administration (FDA) - approved uricase therapy in adult patients with chronic refractory gout.

  • GlobeNewswire3 months ago

    Selecta Biosciences Announces New Employment Inducement Grant

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Elona Kogan, J.D. commenced her services as the company’s General Counsel and Corporate Secretary. In connection with the commencement of Ms. Kogan’s services, the company issued to Ms. Kogan an option to purchase an aggregate of 400,000 shares of the company’s common stock with a per share exercise price of $2.29, the closing trading price of the company’s common stock on the Nasdaq Global Market on March 25, 2019, and 100,000 performance-based restricted stock units.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SELB earnings conference call or presentation 15-Mar-19 12:30pm GMT

    Q4 2018 Selecta Biosciences Inc Earnings Call

  • GlobeNewswire3 months ago

    Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

    Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19Collaboration with CureCN projected to dose.

  • GlobeNewswire3 months ago

    Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it will report its fourth quarter full year end 2018 financial results and provide a corporate update before the open of the U.S. financial markets on Friday, March 15, 2019. At 8:30 a.m. ET that day, Selecta will host a conference call and live audio webcast to discuss the year end 2018 financial results and provide a corporate update. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.

  • GlobeNewswire3 months ago

    Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019

    WATERTOWN, Mass., March 06, 2019 -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of.

  • IBD Stock Of The Day: Top-Rated Pharma Stock Approaches Breakout
    Investor's Business Daily4 months ago

    IBD Stock Of The Day: Top-Rated Pharma Stock Approaches Breakout

    Horizon Pharma is the IBD Stock Of The Day as shares approach a buy point amid bullish calls for its experimental eye disease treatment. One analyst expects it to be the standard of care.

  • GlobeNewswire5 months ago

    Selecta Biosciences Announces Pricing of Public Offering of Common Stock

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $1.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $30.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Selecta.

  • Benzinga5 months ago

    The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...

  • GlobeNewswire5 months ago

    Selecta Biosciences Announces Proposed Public Offering of Common Stock

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Canaccord Genuity and Needham & Company are acting as co-lead managers, and Janney Montgomery Scott is acting as co-manager for the offering. Selecta intends to use the net proceeds from the offering, in addition to its existing cash resources, to advance the clinical development of SEL-212, including the completion of a head-to-head superiority trial of SEL-212 compared to the current FDA-approved uricase therapy, completion of the Phase 2 clinical trial and preparations for a Phase 3 clinical trial, for other pre-clinical programs, including gene therapy development work, and for other operational activities and general corporate purposes.

  • Selecta Biosciences Enters Oversold Territory
    Zacks5 months ago

    Selecta Biosciences Enters Oversold Territory

    Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Watertown biotech Selecta drops cancer drug, cuts staff
    American City Business Journals5 months ago

    Watertown biotech Selecta drops cancer drug, cuts staff

    Selecta Biosciences has announced plans to cut more than a third of its employees and shelve a cancer drug following various trial problems late last year. The Watertown biotech said it will eliminate 36 percent of its staff positions as part of a company restructuring. Selecta (Nasdaq: SELB) had 64 full-time employees as of January 2018, according to a federal filing.

  • GlobeNewswire5 months ago

    Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.

    “We believe 2019 will be a transformative year for Selecta with key milestones anticipated for both our chronic refractory gout and gene therapy programs. Based on interim data from the recently completed Phase 2 study, inclusive of the five outstanding patients who had not previously completed their course of therapy as of October 9th, 2018, 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of

  • What Kind Of Shareholder Appears On The Selecta Biosciences Inc’s (NASDAQ:SELB) Shareholder Register?
    Simply Wall St.6 months ago

    What Kind Of Shareholder Appears On The Selecta Biosciences Inc’s (NASDAQ:SELB) Shareholder Register?

    Every investor in Selecta Biosciences Inc (NASDAQ:SELB) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswire6 months ago

    Selecta Biosciences Announces New Employment Inducement Grants

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Carsten Brunn, Ph.D. commenced his services as the company’s Chief Executive Officer on December 1, 2018. In connection with the commencement of Dr. Brunn’s services, the company issued to Dr. Brunn an option to purchase an aggregate of 1,000,000 shares of the company’s common stock with a per share exercise price of $6.03, the closing trading price of the company’s common stock on the Nasdaq Global Market on November 30, 2018, and 175,000 restricted stock units.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of SELB earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Selecta Biosciences Inc Earnings Call